CoChat

GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy

Open access
Mukha, Anna, Kahya, Uğur, Linge, Annett, Chen, Oleg, Löck, Steffen, Lukiyanchuk, Vasyl, Richter, Susan, Alves, Tiago C., Peitzsch, Mirko, Telychko, Vladyslav, Skvortsov, Sergej, Negro, Giulia, Aschenbrenner, Bertram, Skvortsova, Ira-Ida, Mirtschink, Peter, Lohaus, Fabian, Hölscher, Tobias, Neubauer, Hans, Rivandi, Mahdi, Labitzky, Vera, Lange, Tobias, Franken, André, Behrens, Bianca, Stoecklein, Nikolas H., Toma, Marieta, Sommer, Ulrich, Zschaeck, Sebastian, Rehm, Maximilian, Eisenhofer, Graeme, Schwager, Christian, Abdollahi, Amir, Groeben, Christer, Kunz-Schughart, Leoni A., Baretton, Gustavo B., Baumann, Michael, Krause, Mechthild, Peitzsch, Claudia, Dubrovska, Anna · 2021 · Theranostics
Cited by 182

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Abstract Radiotherapy is one of the curative treatment options for localized prostate cancer (PCa). The curative potential of radiotherapy is mediated by irradiation-induced oxidative stress and DNA damage in tumor cells. However, PCa radiocurability can be impeded by tumor resistance mechanisms and normal tissue toxicity. Metabolic reprogramming is one of the major hallmarks of tumor progression and therapy resistance. Here, we found that radioresistant PCa cells and prostate cancer stem cells (CSCs) have a high glutamine demand. Glutaminase (GLS)-driven catabolism of glutamine serves not only for energy production but also for the maintenance of the redox state. Consequently, glutamine depletion or inhibition of critical regulators of glutamine utilization, such as glutaminase (GLS) and the transcription factor MYC results in PCa radiosensitization. On the contrary, we found that a combination of glutamine metabolism inhibitors with irradiation does not cause toxic effects on nonmalignant prostate cells. Glutamine catabolism contributes to the maintenance of CSCs through regulation of the alpha-ketoglutarate (α-KG)-dependent chromatin-modifying dioxygenase. The lack of glutamine results in the inhibition of CSCs with a high aldehyde dehydrogenase (ALDH) activity, decreases the frequency of the CSC populations in vivo and reduces tumor formation in xenograft mouse models. Moreover, this study shows that activation of the ATG5-mediated autophagy in response to a lack of glutamine is a tumor survival strategy to withstand radiation-mediated cell damage. In combination with autophagy inhibition, the blockade of glutamine metabolism might be a promising strategy for PCa radiosensitization. High blood levels of glutamine in PCa patients significantly correlate with a shorter prostate-specific antigen (PSA) doubling time. Furthermore, high expression of critical regulators of glutamine metabolism, GLS1 and MYC, is significantly associated with a decreased progression-free survival in PCa patients treated with radiotherapy. Our findings demonstrate that GLS-driven glutaminolysis is a prognostic biomarker and therapeutic target for PCa radiosensitization.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7150/thno.58655

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

Metadata

Authors
Mukha, A., Kahya, U., Linge, A., Chen, O., Löck, S., Lukiyanchuk, V., Richter, S., Alves, T. C., Peitzsch, M., Telychko, V., Skvortsov, S., Negro, G., Aschenbrenner, B., Skvortsova, I.-I., Mirtschink, P., Lohaus, F., Hölscher, T., Neubauer, H., Rivandi, M., Labitzky, V., Lange, T., Franken, A., Behrens, B., Stoecklein, N. H., Toma, M., Sommer, U., Zschaeck, S., Rehm, M., Eisenhofer, G., Schwager, C., Abdollahi, A., Groeben, C., Kunz-Schughart, L. A., Baretton, G. B., Baumann, M., Krause, M., Peitzsch, C., & Dubrovska, A.
Venue
Theranostics
Published
2021
Volume
11
Issue
16
Pages
7844-7868
ISSN
1838-7640 (ISSN-L)
OpenAlex
W3183325603
Cited by
182
References
13
FWCI
8.83
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.